AHA - American Hospital Association
07/31/2025 | Press release | Distributed by Public on 07/31/2025 10:05
AHA Statement on 340B Rebate Guidance
Aimee Kuhlman
Vice President, Advocacy and Grassroots
American Hospital Association
July 31, 2025
The AHA looks forward to reviewing HRSA's 340B rebate guidance in more detail and working with the agency on this issue. However, we are concerned that this guidance authorizes a significant departure from how the 340B program has successfully operated for decades and sets a dangerous precedent for possible harmful expansions in the future. This pilot program is a response to a non-existent program integrity problem that the drug manufacturers have manufactured in the public discourse.
Nevertheless, we appreciate HRSA's efforts to impose strict guardrails on its limited pilot program. Going forward, it will be essential that HRSA makes certain that the drug companies bear all the costs of implementing these rebate models and that those companies provide discounts expeditiously. Anything else will pose serious financial risks to patients, communities, and the hospitals that care for them.
###
AHA - American Hospital Association published this content on July 31, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 31, 2025 at 16:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]